background preloader

Health

Facebook Twitter

Preparing for a long hospital stay « My Lymphoma Journey. Planning a lengthy hospital stay is like planning any extended vacation or business trip, with the difference that transitioning to hospital life means transitioning to no longer being in control, where choice is limited, and where one is dependent on others. Depending on your treatment and possible complications, you may end up spending a fair amount of time in the hospital (I spent close to a combined two months during each of my auto and allo SCTs, with roughly half of that in isolation).

Get your life in order: Faced with cancer treatment, the cliché of getting your affairs in order, medical-speak for possible death, applies. It means joint bank accounts, an up-to-date will, a personal care power of attorney with a ‘Do not resuscitate’ clause if that is your wish, and any other instructions that will make it easier for family members should the unfortunate happen. On the emotional side, if there is need for family or other reconciliations, do it now rather than later. Be patient. Cancer Experience Registry. Formerly known as Cancer Survivor Registry: The Breast Cancer M.A.P Project If sharing your cancer journey could enhance the lives of others would you help? What is the Cancer Experience Registry? It is a community of people touched by cancer. The primary focus is on collecting, analyzing and sharing information about the experience and needs of the patient and family throughout the cancer journey.

Why is a Cancer Registry Important? There is a need to include social and emotional care as an integral part of cancer care. The information collected from the cancer registry will be used to inform the future of cancer care, develop programs and offer services to more effectively address the emotional and social needs of people affected by cancer. Who is Eligible to Participate in the Cancer Experience Registry? It is open to people touched by any type of cancer. How Can I Participate? If you have ever been diagnosed with cancer, please join now and share your experience with us.

Headache Center | Patients & Visitors | Dartmouth-Hitchcock. Mantle Cell lymphoma. Mantle cell lymphoma is an aggressive variety of lymphoma which is typically found in the lymph nodes, spleen, marrow and blood. It is unique in that it is classified as an aggressive variety of lymphoma and yet it sometimes behaves as an indolent lymphoma. Most typically it behaves aggressively and is more difficult to treat than other indolent lymphomas. Mantle cell lymphoma is called that because it usually infiltrates the Mantle Zone of the lymph nodes.

That is the area surrounding the lymphoid follicles. When it remains in the mantle zone it generally follows a more indolent course. When it spreads outside this area, in a more diffuse growth pattern, its behaviour becomes less indolent and more aggressive. Diagnosis and Prognosis It is typically characterized by the expression of CD5, over expression of Cyclin D1 and the t(11:14) chromosomal translocation. Mantle Cell Lymphoma, is there a potential for a cure; from Clinical Options Biology and bio-pathology of mantle cell lymphoma. Front-line treatment of mantle cell lymphoma. In this issue of the Journal, Gressin et al.1 publish the results of two phase II trials on newly diagnosed mantle cell lymphoma (MCL). In the first trial (LM1996), the treatment was infusion based vincristine and doxorubicin, oral dexamethasone and chlorambucil (VADC). Elderly patients received eight series while younger patients received six followed by high-dose melphalan and total-body irradiation with autologous stem cell transplantation (ASCT).

In the subsequent LM2001 trial, younger patients (<65 years) received six cycles of VADC + rituximab (R-VADC) followed by ASCT. The reported outcome following VADC and R-VADC of all patients is about 45% complete response rate and an over 70% overall response rate. Induction therapy Even though the role of anthracyclins in mantle cell lymphoma has been under doubt ever since this entity was first recognized as centrocytic lymphoma,2 CHOP has been regarded by many to be the standard therapy. Autologous stem cell transplantation Figure 1.

Dr. Front-line treatment of mantle cell lymphoma. In this issue of the Journal, Gressin et al.1 publish the results of two phase II trials on newly diagnosed mantle cell lymphoma (MCL). In the first trial (LM1996), the treatment was infusion based vincristine and doxorubicin, oral dexamethasone and chlorambucil (VADC). Elderly patients received eight series while younger patients received six followed by high-dose melphalan and total-body irradiation with autologous stem cell transplantation (ASCT). In the subsequent LM2001 trial, younger patients (<65 years) received six cycles of VADC + rituximab (R-VADC) followed by ASCT. The reported outcome following VADC and R-VADC of all patients is about 45% complete response rate and an over 70% overall response rate. There was a significant progression free and overall survival advantage of ASCT (transplant was only offered to younger patients). Induction therapy Two regimems which introduce early high-dose cytarabine are HyperCVAD + Mtx/AraC and the Nordic maxi-CHOP/AraC.

Figure 1. Footnotes. Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies - Full Text View. Primary Outcome Measures: Rates of successful engraftment. [ Time Frame: Anytime after Bone Marrow Transplant ] [ Designated as safety issue: No ] Secondary Outcome Measures: Complete donor chimerism [ Time Frame: Chimeric studies will be undertaken on post-transplant days +30, +60, +100, +180 and +365 ] [ Designated as safety issue: No ] Graft-versus-host disease (acute and chronic) [ Time Frame: Any time after Bone Marrow Transplant ] [ Designated as safety issue: No ] Mortality [ Time Frame: Any time after Bone Marrow Transplant ] [ Designated as safety issue: No ] Toxicity [ Time Frame: Until the 6th Bone Marrow Transplant ] [ Designated as safety issue: Yes ] Tumor Response Rate [ Time Frame: Anytime after Bone Marrow Transplant ] [ Designated as safety issue: No ] Allogeneic bone marrow transplantation (BMT) became feasible in the 1960s after elucidation of the Human Leukocyte Antigen (HLA) complex.

Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma - Full Text View. Experimental: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR. This is a phase I/phase II multi-institution trial. The phase I part of the trial will determine the MTD of cytarabine. The phase II part of the trial will examine the efficacy of the proposed regimen by evaluating the 3-year event-free survival (EFS) in patients with untreated mantle cell lymphoma. All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR. INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Other Names:HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL RESCUE (ASCR)Patients admitted to the hospital for high dose chemotherapy.

Potential key to new treatment for mantle cell lymphoma (MCL) Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse. Their study appears in a recent issue of Cancer Research, published by the American Association for Cancer Research.

"Despite good initial response to first-line treatment with chemotherapy and monoclonal antibodies, almost all patients with MCL will eventually relapse," said Eduardo M. Sotomayor, M.D., a senior member at Moffitt and the Susan and John Sykes Endowed Chair for Hematologic Malignancies. "MCL has one of the worst prognoses among all B-cell non-Hodgkin lymphomas. " There have been other, similar attempts to induce an immune response, the authors noted.

Mantle Cell Lymphoma (MCL) Mantle Cell Lymphoma Mantle Cell lymphoma (MCL) is a cancer of b-cells (lymphocytes) - a type of blood cell that protects against infection as part of the immune system. Most lymphoma develop from an acquired (not inherited) injury to the DNA in the genes of a single cell - the cell of origin. ... The defects are passed on with each cell division, giving the defective lymphocytes a growth and survival advantages over normal cells.

So when a lymphoma develops cell division is not balanced by cell death. The median age at diagnosis for MCL is between 60-70 years and most affected by this condition are men (75-80%). MCL is almost always widespread (systemic) when diagnosed -- showing as stage III/IV disease with "extra nodal involvement" - meaning that tumors may also form outside of the Lymphatic System. As of this writing (2013), the regular way to treat MCL has been focused on aggressive first treatment for younger patients - with an option for transplant. Technical - pathology: Workup. Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving High-Dose Therapy and Autologous Stem-Cell Transplantation. Assistance by Diagnosis - Lymphoma :: CFAC - Cancer Financial Assistance Coalition.

The Leukemia & Lymphoma Society® - Official Website. Publications and Products | BMT InfoNet. Indolent mantle cell leukemia: a clinicopathol... [Haematologica. 2011. Focus on Mantle Cell Lymphoma | MCL. Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma - Full Text View. This study is currently recruiting participants. Verified November 2011 by Weill Medical College of Cornell University Sponsor: Collaborator: Celgene Corporation Information provided by (Responsible Party): Weill Medical College of Cornell University ClinicalTrials.gov Identifier: First received: March 24, 2011 Last updated: November 10, 2011 Last verified: November 2011 This is a phase II, multicenter study to determine the efficacy and safety of first-line lenalidomide plus rituximab therapy in patients with mantle cell lymphoma who have received no prior systemic therapy.

Primary Outcome Measures: To evaluate the efficacy of lenalidomide and rituximab based on Change in tumor burden from baseline (Cheson criteria) [ Time Frame: baseline, every 3 months for 3 years, then every 6 months for 2 years ] [ Designated as safety issue: No ]subjects will have CT scans at baseline and every 3 months - Cheson criteria will be used to determine response to treatment Induction Phase (week 1 - 48):